Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
50 studies found for:    ARSENIC ACID
Show Display Options
Rank Status Study
21 Recruiting Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)
Condition: Acute Promyelocytic Leukemia
Interventions: Drug: Realgar-Indigo naturalis formula;   Drug: all-trans retinoic acid;   Drug: Arsenic trioxide;   Drug: Hydroxyurea
22 Recruiting Acute Promyelocytic Leukemia (APL) Treated With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin
Condition: Leukemia
Interventions: Drug: ATRA;   Drug: ATO;   Drug: GO (Gemtuzumab ozogamicin);   Drug: Methylprednisolone
23 Completed Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia
Condition: Myelodysplastic Syndromes and Leukemia, Myeloid, Acute
Interventions: Drug: Arsenic Trioxide;   Drug: Decitabine
24 Completed Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia
Conditions: Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Promyelocytic Leukemia (M3);   Childhood Acute Promyelocytic Leukemia (M3);   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: Drug: tretinoin;   Drug: daunorubicin hydrochloride;   Drug: cytarabine;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: arsenic trioxide
25 Terminated Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy
Condition: Metastatic Melanoma
Interventions: Drug: Disulfiram;   Drug: Arsenic trioxide
26 Not yet recruiting Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer
Condition: Skin Basal Cell Carcinoma
Interventions: Drug: Arsenic Trioxide;   Drug: Itraconazole;   Other: Laboratory Biomarker Analysis
27 Active, not recruiting Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Conditions: Childhood Acute Promyelocytic Leukemia (M3);   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: Drug: arsenic trioxide;   Drug: mitoxantrone hydrochloride;   Other: diagnostic laboratory biomarker analysis;   Drug: idarubicin;   Drug: tretinoin;   Drug: cytarabine;   Drug: mercaptopurine tablet;   Drug: methotrexate
28 Completed Effect of Spirulina on Zinc, Vitamin E and Linoleic Acid Levels in Palm Skin Following Chronic Exposure to Arsenic
Condition: Arsenical Keratosis
Intervention: Dietary Supplement: Spirulina
29 Recruiting Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
Condition: Acute Promyelocytic Leukemia
Interventions: Drug: Arsenic trioxide;   Drug: Idarubicin;   Drug: Cytarabine;   Drug: Tretinoin;   Drug: Mitoxantrone;   Drug: Mercaptopurine;   Drug: Methotrexate
30 Completed Arsenic Trioxide in Treating Patients With Urothelial Cancer
Conditions: Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Urethral Cancer;   Transitional Cell Carcinoma of the Bladder;   Ureter Cancer
Intervention: Drug: arsenic trioxide
31 Withdrawn Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: arsenic trioxide;   Other: laboratory biomarker analysis
32 Terminated Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction
Conditions: Adenocarcinoma of the Esophagus;   Stage III Esophageal Cancer;   Stage IV Esophageal Cancer
Intervention: Drug: arsenic trioxide
33 Completed Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma
Conditions: Basal Cell Carcinoma of the Skin;   Recurrent Skin Cancer
Interventions: Drug: arsenic trioxide;   Other: laboratory biomarker analysis
34 Terminated Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia
Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Prolymphocytic Leukemia;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Splenic Marginal Zone Lymphoma;   Waldenström Macroglobulinemia
Interventions: Drug: arsenic trioxide;   Other: laboratory biomarker analysis
35 Completed Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: pamidronate disodium;   Drug: arsenic trioxide;   Other: laboratory biomarker analysis;   Other: pharmacological study
36 Completed Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma
Interventions: Drug: arsenic trioxide;   Radiation: radiation therapy
37 Enrolling by invitation A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia
Condition: Childhood Acute Promyelocytic Leukemia
Interventions: Drug: ATO;   Drug: RIF;   Drug: ATRA;   Drug: mitoxantrone;   Drug: Ara-C;   Drug: MTX;   Drug: 6MP;   Other: intrathecal injection
38 Unknown  Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC
Condition: Carcinoma, Hepatocellular
Interventions: Drug: TACE containing As2O3;   Drug: TACE containing placebo
39 Completed Effects of Leaf Extract of Azadirachta Indica in Palmer Arsenical Keratosis
Condition: Arsenical Keratosis
Interventions: Other: Leaf extract of A. indica;   Drug: Salicylic Acid (6%);   Other: Petroleum jelly
40 Active, not recruiting Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
Condition: Acute Promyelocytic Leukemia
Intervention: Drug: Tretinoin and Arsenic Trioxide

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-50) Show next page of results    Last Page
Indicates status has not been verified in more than two years